Skip to main content
Castle Creek to acquire Fibrocell in $63.3M deal

Fibrocell Science, a cell and gene therapy developer, has agreed to be acquired by Castle Creek Pharmaceuticals for $63.3 million. As part of the deal, Castle Creek will pay Fibrocell an upfront payment of $7.5 million plus milestone payments of up to $135 million related to its new drug candidates.

Full Story: